Sep. 12 at 1:18 PM
$AQST What a hot tape does to a
$4.80 name when each headline hits clean.
Anaphylm resubmission accepted — late Q3 / early Q4 ’26 —
$5.50–
$6.00
FDA files it and sets a clock — weeks later —
$6.50–
$7.25
Canada NDS filed — YE ’26 —
$7.00–
$8.00
Libervant US deal or solo launch build — before January —
$8–
$10
Libervant 6–11 / age-expansion PR — through 1H ’27 —
$9–
$11
Anaphylm US approval — ’27 —
$12–
$16
Anaphylm EU MAA filed — Q1 ’27 —
$13–
$17
Libervant US unlocked Jan ’27 + first scripts — Q1–Q2 ’27 —
$14–
$18
Anaphylm EU/UK approval — ’27–’28 —
$16–
$22
AQST-108 AD or alopecia data — ’27 — supports
$20
7-product royalties + insurance uptake — ’27 run-rate — high teens to
$20S
